Barclays PLC Purchases 124,667 Shares of ProKidney Corp. (NASDAQ:PROK)

Barclays PLC boosted its position in shares of ProKidney Corp. (NASDAQ:PROK) by 575.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 146,321 shares of the company’s stock after acquiring an additional 124,667 shares during the period. Barclays PLC’s holdings in ProKidney were worth $281,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Suvretta Capital Management LLC raised its position in shares of ProKidney by 32.1% during the third quarter. Suvretta Capital Management LLC now owns 12,341,266 shares of the company’s stock valued at $23,695,000 after buying an additional 3,000,000 shares during the last quarter. State Street Corp boosted its stake in ProKidney by 16.2% during the third quarter. State Street Corp now owns 1,428,318 shares of the company’s stock worth $2,742,000 after buying an additional 198,836 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in ProKidney by 150.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 749,718 shares of the company’s stock worth $1,439,000 after buying an additional 450,548 shares during the period. Bank of New York Mellon Corp boosted its stake in ProKidney by 44.6% during the second quarter. Bank of New York Mellon Corp now owns 179,236 shares of the company’s stock worth $441,000 after buying an additional 55,266 shares during the period. Finally, Rhumbline Advisers boosted its stake in ProKidney by 8.8% during the second quarter. Rhumbline Advisers now owns 76,190 shares of the company’s stock worth $187,000 after buying an additional 6,181 shares during the period. Institutional investors own 51.59% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PROK. JPMorgan Chase & Co. began coverage on shares of ProKidney in a research note on Monday, September 30th. They set a “neutral” rating for the company. Guggenheim began coverage on shares of ProKidney in a research note on Tuesday, September 10th. They set a “buy” rating and a $6.00 target price for the company. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $4.50.

ProKidney Price Performance

PROK stock opened at $1.86 on Monday. The business has a 50-day moving average price of $1.82 and a 200 day moving average price of $2.05. The company has a market capitalization of $542.49 million, a P/E ratio of -3.38 and a beta of 1.32. ProKidney Corp. has a 1-year low of $1.18 and a 1-year high of $4.44.

ProKidney (NASDAQ:PROK) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.14) earnings per share for the quarter, meeting the consensus estimate of ($0.14). On average, analysts anticipate that ProKidney Corp. will post -0.57 earnings per share for the current fiscal year.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.